At the time of writing, ImmunityBio Inc [IBRX] stock is trading at $3.02, up 5.96%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The IBRX shares have lost -0.33% over the last week, with a monthly amount drifted -12.46%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
ImmunityBio Inc [NASDAQ: IBRX] stock has seen the most recent analyst activity on January 10, 2025, when BTIG Research initiated its Buy rating and assigned the stock a price target of $6. Previously, Piper Sandler downgraded its rating to Neutral on May 12, 2023, and dropped its price target to $4. On August 03, 2022, Jefferies initiated with a Buy rating and assigned a price target of $8 on the stock.
For the past year, the stock price of ImmunityBio Inc fluctuated between $2.28 and $10.53. Currently, Wall Street analysts expect the stock to reach $6 within the next 12 months. ImmunityBio Inc [NASDAQ: IBRX] shares were valued at $3.02 at the most recent close of the market. An investor can expect a potential return of 98.68% based on the average IBRX price forecast.
Analyzing the IBRX fundamentals
According to ImmunityBio Inc [NASDAQ:IBRX], the company’s sales were 14.74M for trailing twelve months, which represents an 5333.09% jump. Gross Profit Margin for this corporation currently stands at 0.69% with Operating Profit Margin at -23.34%, Pretax Profit Margin comes in at -28.05%, and Net Profit Margin reading is -28.05%. To continue investigating profitability, this company’s Return on Assets is posted at -1.08, Equity is 0.63 and Total Capital is -0.9.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.76 points at the first support level, and at 2.49 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.23, and for the 2nd resistance point, it is at 3.43.
Ratios To Look Out For
It is important to note that ImmunityBio Inc [NASDAQ:IBRX] has a current ratio of 3.36. In addition, the Quick Ratio stands at 3.21. Considering the valuation of this stock, the price to sales ratio is 149.60.
